248 related articles for article (PubMed ID: 18078017)
1. Clinical use of recombinant human activated factor VII (rFVIIa) in the prevention and treatment of bleeding episodes in patients with Glanzmann's thrombasthenia.
Poon MC
Vasc Health Risk Manag; 2007; 3(5):655-64. PubMed ID: 18078017
[TBL] [Abstract][Full Text] [Related]
2. The Use of Recombinant Activated Factor VII in Patients with Glanzmann's Thrombasthenia.
Poon MC
Thromb Haemost; 2021 Mar; 121(3):332-340. PubMed ID: 33124022
[TBL] [Abstract][Full Text] [Related]
3. New Insights Into the Treatment of Glanzmann Thrombasthenia.
Poon MC; Di Minno G; d'Oiron R; Zotz R
Transfus Med Rev; 2016 Apr; 30(2):92-9. PubMed ID: 26968829
[TBL] [Abstract][Full Text] [Related]
4. Glanzmann's thrombasthenia treatment: a prospective observational registry on the use of recombinant human activated factor VII and other hemostatic agents.
Poon MC; Zotz R; Di Minno G; Abrams ZS; Knudsen JB; Laurian Y
Semin Hematol; 2006 Jan; 43(1 Suppl 1):S33-6. PubMed ID: 16427383
[TBL] [Abstract][Full Text] [Related]
5. Use of recombinant activated factor VII in patients with Glanzmann's thrombasthenia: a review of the literature.
Rajpurkar M; Chitlur M; Recht M; Cooper DL
Haemophilia; 2014 Jul; 20(4):464-71. PubMed ID: 24948404
[TBL] [Abstract][Full Text] [Related]
6. NovoSeven (recombinant factor VIIa) for the treatment of bleeding episodes and perioperative management in patients with Glanzmann's thrombasthenia.
Franchini M; Lippi G
Expert Rev Hematol; 2014 Dec; 7(6):733-40. PubMed ID: 25387838
[TBL] [Abstract][Full Text] [Related]
7. Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey.
Poon MC; D'Oiron R; Von Depka M; Khair K; Négrier C; Karafoulidou A; Huth-Kuehne A; Morfini M;
J Thromb Haemost; 2004 Jul; 2(7):1096-103. PubMed ID: 15219192
[TBL] [Abstract][Full Text] [Related]
8. Independent adjudicator assessments of platelet refractoriness and rFVIIa efficacy in bleeding episodes and surgeries from the multinational Glanzmann's thrombasthenia registry.
Recht M; Rajpurkar M; Chitlur M; d'Oiron R; Zotz R; Di Minno G; Cooper DL; Poon MC
Am J Hematol; 2017 Jul; 92(7):646-652. PubMed ID: 28370369
[TBL] [Abstract][Full Text] [Related]
9. Low Concentrations of Recombinant Factor VIIa May Improve the Impaired Thrombin Generation of Glanzmann Thrombasthenia Patients.
Levy-Mendelovich S; Levy T; Budnik I; Barg AA; Rosenberg N; Seligsohn U; Kenet G; Livnat T
Thromb Haemost; 2019 Jan; 119(1):117-127. PubMed ID: 30597506
[TBL] [Abstract][Full Text] [Related]
10. The evidence for the use of recombinant human activated factor VII in the treatment of bleeding patients with quantitative and qualitative platelet disorders.
Poon MC
Transfus Med Rev; 2007 Jul; 21(3):223-36. PubMed ID: 17572261
[TBL] [Abstract][Full Text] [Related]
11. Eptacog alfa activated: a recombinant product to treat rare congenital bleeding disorders.
Di Minno G
Blood Rev; 2015 Jun; 29 Suppl 1():S26-33. PubMed ID: 26073366
[TBL] [Abstract][Full Text] [Related]
12. Control of severe bleeding episode in case of Glanzmann's thrombasthenia refractory to platelet transfusion therapy by administering recombinant factor VIIa.
Javed A; Ayyub M; Abrar S; Mansoor M; Khan B; Hussain T
J Ayub Med Coll Abbottabad; 2009; 21(2):171-3. PubMed ID: 20524499
[TBL] [Abstract][Full Text] [Related]
13. Use of recombinant factor VIIa in 3 patients with inherited type I Glanzmann's thrombasthenia undergoing invasive procedures.
d'Oiron R; Ménart C; Trzeciak MC; Nurden P; Fressinaud E; Dreyfus M; Laurian Y; Négrier C
Thromb Haemost; 2000 May; 83(5):644-7. PubMed ID: 10823254
[TBL] [Abstract][Full Text] [Related]
14. Intensive menstrual bleeding successfully treated with recombinant factor VIIa in Glanzmann thrombasthenia.
Balci YI; Karabulut A; Kabukcu S; Sari I; Keskin A
Clin Appl Thromb Hemost; 2011 Aug; 17(4):320-2. PubMed ID: 20460355
[TBL] [Abstract][Full Text] [Related]
15. Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia.
Poon MC; Demers C; Jobin F; Wu JW
Blood; 1999 Dec; 94(11):3951-3. PubMed ID: 10572113
[TBL] [Abstract][Full Text] [Related]
16. Treatment of bleeding in patients with platelet disorders: is there a place for recombinant factor VIIa?
Laurian Y
Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():37-40. PubMed ID: 12214146
[TBL] [Abstract][Full Text] [Related]
17. Perioperative management of a pediatric patient with Glanzmann's thrombasthenia during adenoidectomy.
Duman EN; Saylan S; Cekic B
Rev Bras Anestesiol; 2012 Jul; 62(4):548-53. PubMed ID: 22793971
[TBL] [Abstract][Full Text] [Related]
18. The use of recombinant FVIIa in a patient with Glanzmann thrombasthenia with uncontrolled bleeding after tonsillectomy.
Erduran E; Aksoy A; Zaman D
Blood Coagul Fibrinolysis; 2009 Apr; 20(3):215-7. PubMed ID: 19657319
[TBL] [Abstract][Full Text] [Related]
19. The international, prospective Glanzmann Thrombasthenia Registry: treatment and outcomes in surgical intervention.
Poon MC; d'Oiron R; Zotz RB; Bindslev N; Di Minno MN; Di Minno G;
Haematologica; 2015 Aug; 100(8):1038-44. PubMed ID: 26001792
[TBL] [Abstract][Full Text] [Related]
20. Successful surgery using recombinant factor VIIa for recurrent, idiopathic nonulcer duodenal bleeding in a patient with Glanzmann's thrombasthenia.
van Buuren HR; Wielenga JJ
Dig Dis Sci; 2002 Sep; 47(9):2134-6. PubMed ID: 12353868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
